Riken Corporation

Kyushu University

Daisuke Takaya

Shigeyuki Yokoyama

Motomu Kanai

Yoshinori Fukui

Takahiro Shirai

Shigeki Matsunaga

Takehito Uruno

Soichi Kojima

Teruki Honma

Takehisa Matsumoto

Mutsuko Niino

Mitsuko Hara

The present invention provides a compound capable of being used as an active ingredient of an anti-cancer agent. To provide an anti-cancer agent with few side effects, an object of the present invention is to provide a compound capable of selectively inhibiting the target, i.e., DOCK1, or a salt thereof. The pyridinone compound of the present invention is represented by Formula (1):  

Pyridinone compound and use thereof

An object is to provide a compound capable of inhibiting activation of TGF-&#x3b2; receptors due to HCV, and a screening method for the compound. It has been found that a HCV-derived NS3 protease binds to type I TGF-&#x3b2; receptor, and this binding results in activation of TGF-&#x3b2; receptors. Moreover, binding sites between the NS3 protease and type I TGF-&#x3b2; receptor were identified, and it has been found that antibodies recognizing these binding sites inhibit activation of TGF-&#x3b2; receptors due to NS3 protease. Furthermore, it has been also found that screening for a compound capable of inhibiting activation of TGF-&#x3b2; receptors can be performed by using the inhibition of the binding between NS3 protease and type I TGF-&#x3b2; receptor or the like as an index.

Compounds having activity of suppressing activation of TGF-&#x3b2; receptor, method for screening of the compounds, and composition for preventing or treating disease caused by hepatitis C virus

Growing community of inventors

Yokohama, Japan

Daisuke Takaya